Cargando…
Construction and evaluation of a novel humanized HER2-specific chimeric receptor
INTRODUCTION: The human epidermal growth factor receptor 2 (HER2) represents one of the most studied tumor-associated antigens (TAAs) for cancer immunotherapy. The monoclonal antibody (mAb) trastuzumab has improved the outcomes of patients with HER2+ breast cancer. However, a large number of HER2+ t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4095682/ https://www.ncbi.nlm.nih.gov/pubmed/24919843 http://dx.doi.org/10.1186/bcr3674 |
_version_ | 1782326076339388416 |
---|---|
author | Sun, Meili Shi, Huan Liu, Chuanyong Liu, Jie Liu, Xianqiang Sun, Yuping |
author_facet | Sun, Meili Shi, Huan Liu, Chuanyong Liu, Jie Liu, Xianqiang Sun, Yuping |
author_sort | Sun, Meili |
collection | PubMed |
description | INTRODUCTION: The human epidermal growth factor receptor 2 (HER2) represents one of the most studied tumor-associated antigens (TAAs) for cancer immunotherapy. The monoclonal antibody (mAb) trastuzumab has improved the outcomes of patients with HER2+ breast cancer. However, a large number of HER2+ tumors are not responsive to, or become resistant to, trastuzumab-based therapy, and thus more effective therapies targeting HER2 are needed. METHODS: HER2-specific T cells were generated by the transfer of genes that encode chimeric antigen receptor (CAR). Using a multistep overlap extension PCR method, we constructed a novel, humanized HER2 CAR-containing, chA21 single-chain variable fragment (scFv) region of antigen-specific mAb and T-cell intracellular signaling chains made up of CD28 and CD3ζ. An interferon γ and interleukin 2 enzyme-linked immunosorbent assay and a chromium-51 release assay were used to evaluate the antitumor immune response of CAR T cells in coculture with tumor cells. Furthermore, SKBR3 tumor–bearing nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice were treated with HER2 CAR T cells to evaluate antitumor activity. Human CD3+ T cell accumulation in tumor xenograft was detected by immunohistochemistry. RESULTS: chA21-28z CAR was successfully constructed, and both CD4+ and CD8+ T cells were transduced. The expanded HER2 CAR T cells expressed a central memory phenotype and specifically reacted against HER2+ tumor cell lines. Furthermore, the SKBR3 tumor xenograft model revealed that HER2 CAR T cells significantly inhibited tumor growth in vivo. Immunohistochemical analysis showed robust accumulation of human CD3+ T cells in regressing SKBR3 lesions. CONCLUSIONS: The results of this study show that novel chA21 scFv-based, HER2-specific CAR T cells not only recognized and killed HER2+ breast and ovarian cancer cells ex vivo but also induced regression of experimental breast cancer in vivo. Our data support further exploration of the HER2 CAR T-cell therapy for HER2-expressing cancers. |
format | Online Article Text |
id | pubmed-4095682 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40956822014-07-14 Construction and evaluation of a novel humanized HER2-specific chimeric receptor Sun, Meili Shi, Huan Liu, Chuanyong Liu, Jie Liu, Xianqiang Sun, Yuping Breast Cancer Res Research Article INTRODUCTION: The human epidermal growth factor receptor 2 (HER2) represents one of the most studied tumor-associated antigens (TAAs) for cancer immunotherapy. The monoclonal antibody (mAb) trastuzumab has improved the outcomes of patients with HER2+ breast cancer. However, a large number of HER2+ tumors are not responsive to, or become resistant to, trastuzumab-based therapy, and thus more effective therapies targeting HER2 are needed. METHODS: HER2-specific T cells were generated by the transfer of genes that encode chimeric antigen receptor (CAR). Using a multistep overlap extension PCR method, we constructed a novel, humanized HER2 CAR-containing, chA21 single-chain variable fragment (scFv) region of antigen-specific mAb and T-cell intracellular signaling chains made up of CD28 and CD3ζ. An interferon γ and interleukin 2 enzyme-linked immunosorbent assay and a chromium-51 release assay were used to evaluate the antitumor immune response of CAR T cells in coculture with tumor cells. Furthermore, SKBR3 tumor–bearing nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice were treated with HER2 CAR T cells to evaluate antitumor activity. Human CD3+ T cell accumulation in tumor xenograft was detected by immunohistochemistry. RESULTS: chA21-28z CAR was successfully constructed, and both CD4+ and CD8+ T cells were transduced. The expanded HER2 CAR T cells expressed a central memory phenotype and specifically reacted against HER2+ tumor cell lines. Furthermore, the SKBR3 tumor xenograft model revealed that HER2 CAR T cells significantly inhibited tumor growth in vivo. Immunohistochemical analysis showed robust accumulation of human CD3+ T cells in regressing SKBR3 lesions. CONCLUSIONS: The results of this study show that novel chA21 scFv-based, HER2-specific CAR T cells not only recognized and killed HER2+ breast and ovarian cancer cells ex vivo but also induced regression of experimental breast cancer in vivo. Our data support further exploration of the HER2 CAR T-cell therapy for HER2-expressing cancers. BioMed Central 2014 2014-06-11 /pmc/articles/PMC4095682/ /pubmed/24919843 http://dx.doi.org/10.1186/bcr3674 Text en Copyright © 2014 Sun et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Sun, Meili Shi, Huan Liu, Chuanyong Liu, Jie Liu, Xianqiang Sun, Yuping Construction and evaluation of a novel humanized HER2-specific chimeric receptor |
title | Construction and evaluation of a novel humanized HER2-specific chimeric receptor |
title_full | Construction and evaluation of a novel humanized HER2-specific chimeric receptor |
title_fullStr | Construction and evaluation of a novel humanized HER2-specific chimeric receptor |
title_full_unstemmed | Construction and evaluation of a novel humanized HER2-specific chimeric receptor |
title_short | Construction and evaluation of a novel humanized HER2-specific chimeric receptor |
title_sort | construction and evaluation of a novel humanized her2-specific chimeric receptor |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4095682/ https://www.ncbi.nlm.nih.gov/pubmed/24919843 http://dx.doi.org/10.1186/bcr3674 |
work_keys_str_mv | AT sunmeili constructionandevaluationofanovelhumanizedher2specificchimericreceptor AT shihuan constructionandevaluationofanovelhumanizedher2specificchimericreceptor AT liuchuanyong constructionandevaluationofanovelhumanizedher2specificchimericreceptor AT liujie constructionandevaluationofanovelhumanizedher2specificchimericreceptor AT liuxianqiang constructionandevaluationofanovelhumanizedher2specificchimericreceptor AT sunyuping constructionandevaluationofanovelhumanizedher2specificchimericreceptor |